Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
AU2008201162A1
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphavbeta3 antagonists in combination with other prophylactic or therapeutic agents
CN101594882A
Interferon alpha-induced pharmacodynamic markers
WO2008070042A2
High potency recombinant antibodies, methods for producing them and use in cancer therapy
CN101541345A
Stabilized antibody formulations and uses thereof
CN101534859A
Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007136789A2
Methods of preventing, treating or ameliorating enhanced respiratory disease via innate immune mechanisms
WO2007118134A2
A serum-free virus propagation platform for a virus vaccine candidate
US2008003210A1
Non-human primate receptor tyrosine kinases
CA2644906A1
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2007103261A2
Listeria-based epha2 immunogenic compositions
CN101426527A
Protein formulations
WO2007075706A2
Affinity optimized epha2 agonistic antibodies and methods of use thereof
WO2007059300A2
Anti-alk antagonist and agonist antibodies and uses thereof
WO2007047578A2
Cell display of antibody libraries
EP1941275A2
Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US2007071746A1
C/CLP antagonists and methods of use thereof
CA2614181A1
An integrated approach for generating multidomain protein therapeutics
CN101273061A
Antibody formulations having optimized aggregation and fragmentation profiles
